Abstract:SummaryAimsDaphnetin, a coumarin derivative extracted from Daphne odora var. marginata, has been reported to have antiinflammatory and immunosuppressive properties. Our previous study indicated that it was able to remarkably suppress the neuroinflammation and suggested its potential application in treating neuroinflammatory diseases. Multiple sclerosis (MS), a Th cell‐mediated autoimmune disease, is the most common inflammatory demyelinating disease of the central nervous system (CNS). We examined whether daphnetin treatment can protect mice against experimental autoimmune encephalomyelitis (EAE), an animal model for MS.MethodsTo assess the effect of daphnetin in neuroinflammatory diseases, the EAE mice were established and treated with daphnetin at 8 mg/kg for 28 days. The severity of neuroinflammation and demyelination in the spinal cords was examined histopathologically. Infiltration of CD4+ T cells into the CNS was assessed by immunohistochemistry, and the cytokine production was determined by ELISA. Meanwhile, the effect of daphnetin on the activity of dendritic cells (DCs) was evaluated, as assessed by DCs’ capability to express surface markers, secrete cytokines, and activate naïve CD4+ T cells. Furthermore, we explored the molecular mechanisms whereby DAPH regulated DCs’ activity and thereby CD4+ T cell responses.ResultsThe administration of daphnetin markedly alleviated the clinical symptoms of EAE and reduced the CNS inflammation and demyelination in experimental mice. Th1 and Th17 cell responses were profoundly repressed in daphnetin‐treated EAE mice. Mechanistically, daphnetin treatment significantly repressed the activation, maturation, and antigen‐presenting capability of DCs. NF‐κB signaling was significantly reduced in daphnetin‐treated DCs, along with a concomitant induction of heme oxygenase‐1, a negative regulator of inflammatory signaling.ConclusionsOur findings for the first time demonstrate the property of daphnetin in regulating DCs’ function and subsequently Th development. Given the low or absent toxicity associated with daphnetin, our data may suggest a novel safe and effective approach to control autoimmune neuroinflammation.

Oral D-mannose Treatment Suppresses Experimental Autoimmune Encephalomyelitis Via Induction of Regulatory T Cells

D-Mannose Suppresses Oxidative Response and Blocks Phagocytosis in Experimental Neuroinflammation.

D-mannose ameliorates autoimmune phenotypes in mouse models of lupus

D-mannose induces regulatory T cells and suppresses immunopathology

D-mannose Ameliorates Autoimmune Phenotypes in Mouse Models of Lupus.

Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses

Daphnetin Alleviates Experimental Autoimmune Encephalomyelitis Via Regulating Dendritic Cell Activity

Enzymatic Modification of D-mannose Alleviates DSS-induced Colonic Inflammation in Mice Through Macrophage Polarization Mediated by PPARγ.

Mannose enhances intestinal immune barrier function and dextran sulfate sodium salt-induced colitis in mice by regulating intestinal microbiota

Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis.

D-mannose suppresses macrophage release of extracellular vesicles and ameliorates type 2 diabetes

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2

Soluble MOG35-55/I-Ab Dimers Ameliorate Experimental Autoimmune Encephalomyelitis by Reducing Encephalitogenic T Cells

The matrine derivate MASM inhibits astrocyte reactivity and alleviates experimental autoimmune encephalomyelitis in mice

Induction of Regulatory Properties in the Intestinal Immune System by Dimethyl Fumarate in Lewis Rat Experimental Autoimmune Neuritis

Methyl Butyrate Alleviates Experimental Autoimmune Encephalomyelitis and Regulates the Balance of Effector T Cells and Regulatory T Cells

Oral administration of procyanidin B2 3,3"-di-O-gallate ameliorates experimental autoimmune encephalomyelitis through immunosuppressive effects on CD4+ T cells by regulating glycolysis

Abrogation of Endogenous Glycolipid Antigen Presentation on Myelin-Laden Macrophages by D-Sphingosine Ameliorates the Pathogenesis of Experimental Autoimmune Encephalomyelitis.

Amelioration of experimental autoimmune encephalomyelitis by exogenous soluble PD-L1 is associated with restraining dendritic cell maturation and CCR7-mediated migration

9,10-Anhydrodehydroartemisinin Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Th1 and Th17 Cell Differentiation

Dietary protection against the visual and motor deficits induced by experimental autoimmune encephalomyelitis